Ozempic, a prescription medication primarily used to treat type 2 diabetes, has gained attention for its ability to help regulate blood sugar levels. However, as with many medications, the use of Ozempic is not without potential health risks. Patients using this drug have reported side effects ranging from mild digestive issues to more severe conditions like pancreatitis and kidney complications. Understanding these risks is crucial for anyone considering or currently using Ozempic, as it allows for more informed decisions regarding their treatment and health.
In recent years, Ozempic has been the subject of multiple allegations, with claims focusing on the failure to adequately warn users about potential adverse side effects. Some lawsuits have cited that the drug’s manufacturer did not provide sufficient information about the long-term risks, particularly those involving serious health conditions. As these allegations surface, more individuals are coming forward with concerns about the safety of Ozempic and seeking legal action for the harm they may have suffered.
At DV Injury, we are dedicated to protecting your legal rights when it comes to prescription drug injuries. If you or a loved one has been affected by the adverse side effects of Ozempic, you deserve the opportunity to hold the responsible parties accountable. Our experienced legal team is committed to fighting for justice on your behalf, ensuring you receive the compensation you need to cover medical expenses, lost wages, and the pain and suffering endured. Your health and legal rights are our top priority, and we are here to support you every step of the way.
As of November 2024, the multidistrict litigation (MDL) concerning Ozempic, and similar GLP-1 receptor agonist drugs has expanded significantly. The MDL, established in February 2024 in the Eastern District of Pennsylvania, now encompasses 1,221 personal injury lawsuits alleging severe gastrointestinal injuries, including gastroparesis, ileus, and intestinal blockages.
In October 2024, the presiding judge issued a scheduling order focusing on discovery related to the adequacy of the drugs’ warning labels and potential federal preemption issues. The order set a deadline of October 29, 2025, for submitting motions for summary judgment.
In October 2024, litigation involving Ozempic, a diabetes drug also used for weight loss, intensified with a notable increase in filed cases. The multidistrict litigation (MDL) involving Ozempic and similar drugs has now reached over 1,200 cases. This surge reflects growing concerns among patients who allege adverse effects from these medications, including severe gastrointestinal issues like gastroparesis. Early court proceedings are underway, focusing on critical aspects of these cases, such as the adequacy of the warning labels and the legal grounds for preemption.
Individual cases highlight specific grievances. For example, a woman in Georgia filed a lawsuit against Ozempic’s manufacturer, Novo Nordisk, claiming that the drug led to severe and permanent gastroparesis, which impacts stomach motility. She argues that the company failed to adequately warn users of this side effect. Other plaintiffs are bringing similar claims, seeking compensation for the life-altering conditions they allege were caused by the medication.
Meanwhile, the FDA has stepped in, issuing warnings about compounded semaglutide products used for weight loss, which are versions of Ozempic and similar drugs but mixed by compounding pharmacies. In October, the FDA reported 346 adverse events associated with these compounded drugs, emphasizing that they haven’t undergone FDA safety testing, thus posing additional risks to users.
As of September 2024, the Ozempic lawsuits have seen significant developments with over 869 personal injury lawsuits consolidated under MDL 3094 in the Eastern District of Pennsylvania. These lawsuits primarily concern severe gastrointestinal side effects such as gastroparesis, ileus, and intestinal blockages. Lawyers are also investigating cases related to vision loss associated with Ozempic and similar semaglutide drugs like Wegovy. This follows a study linking these medications to nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition causing sudden vision loss.
A major issue in these lawsuits is the claim that Novo Nordisk, the manufacturer of Ozempic, failed to provide adequate warnings about the drug’s potential risks, including severe gastrointestinal complications. The lawsuits argue that while the drug’s label does mention some gastrointestinal side effects, it downplays their severity. Novo Nordisk’s position contrasts with that of Eli Lilly, the manufacturer of Mounjaro, which opposes being included in the consolidated litigation, claiming that their cases are distinct from those involving Ozempic.
Additionally, the death of Judge Gene E. K. Pratter in May 2024, who was overseeing the Ozempic multidistrict litigation (MDL), led to the reassignment of the case to Judge Karen S. Marston. This transition caused some delays, but the litigation is now moving forward. Judge Marston has since been working to keep the litigation on track, with recent orders allowing plaintiffs to file cases directly into the MDL and simplifying the service process. In July of this year, a new study highlighted the risks of semaglutide-related vision loss, and several lawsuits were filed based on this finding. The FDA has also been updating drug labels to reflect new risks associated with these medications, including intestinal blockages and potential links to suicidal thoughts.
Overall, the number of Ozempic-related lawsuits is expected to grow as more patients and healthcare providers become aware of the potential side effects. The outcome of these lawsuits could significantly impact the pharmaceutical industry and Novo Nordisk’s future in the market.
In August, the legal situation surrounding Ozempic, a drug used for diabetes and weight loss, has seen significant developments. There are currently 346 cases pending in the multidistrict litigation (MDL) No. 3094 concerning Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs), which include Ozempic and similar drugs. Following the death of Judge Gene E. K. Pratter in May, U.S. District Judge Karen Marston in Philadelphia has taken over the oversight of these cases.
Several new issues have come to light, including a meta-analysis linking Ozempic and similar drugs to a 266% increase in the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolisms, which has become a focal point of the lawsuits. This research could potentially expand the scope of the litigation. This can bring serious momentum towards these cases, which we are feeling hopeful for.
There are also rising concerns about gastrointestinal issues like gastroparesis (stomach paralysis), which has led to new lawsuits being filed. A notable case was filed by Jaclyn Bjorklund, who suffered severe complications including stomach paralysis after taking Ozempic. This case, along with others, challenges the safety and marketing practices of Novo Nordisk, the drug’s manufacturer. Additionally, the MDL has been a key forum for scientific debates, with recent studies showing links between Ozempic and increased risks of vision problems and bone density reduction. These findings are expected to play a crucial role in the ongoing litigation.
Overall, the lawsuits are focused on the alleged failure of Novo Nordisk to properly warn patients about these serious side effects, leading to claims for damages including medical expenses, pain and suffering, and punitive damages. We want to work towards holding these companies accountable and ensuring our clients receive the compensation they need to recover from damages caused by these products.
The litigation surrounding Ozempic, and other GLP-1 RAs continues to evolve rapidly, with the recent developments significantly impacting the scope and severity of the potential legal claims. The emergence of new scientific evidence, including a meta-analysis linking Ozempic and similar drugs to a 266% increase in the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolisms, has broadened the scope of the lawsuits. This research could potentially lead to additional cases and expand the potential liability for Novo Nordisk.
This conference, if it happened today, would have been the first chance for the new judge, Karen S. Marston, to address the lawyers on both sides (plaintiffs and defendants) about how the case will proceed. They likely discussed deadlines for discovery (exchanging evidence), motions, and potentially a timeline for when trials might begin in individual cases. This is a significant development because it introduces a new potential side effect of Ozempic that wasn’t previously widely known. The details of the study would be important, such as the size and methodology, to understand the strength of the association between Ozempic and vision loss. This could potentially lead to amended complaints from existing plaintiffs or even new lawsuits focusing on vision problems.
This indicates the litigation continues to grow. The lawsuit filed on July 1st exemplifies this with a plaintiff experiencing severe bowel issues allegedly caused by Ozempic. It’s important to note that just because someone files a lawsuit doesn’t mean they’ll win. The courts will need to determine if there’s enough evidence to support their claims.
On July 14, a new case was filed regarding Ozempic. An Illinois man has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging that the companies failed to warn about the risks associated with their weight loss drugs, Ozempic and Mounjaro. The plaintiff was prescribed Ozempic by his endocrinologist in October 2022 for diabetes management and used it until January 2023, after which he switched to Mounjaro for the same purpose.
On June 10, 2023, the plaintiff experienced chest discomfort and severe abdominal pain, leading to hospitalization. A CT scan revealed abnormal thickening in the proximal jejunal small bowel and an internal hernia, indicating ischemia and bowel obstruction. He underwent ischemic bowel resection surgery the following day. The lawsuit, initially filed in Illinois and set to be transferred to a class action in Pennsylvania, seeks compensation for injuries, medical expenses, pain, and suffering due to the defendants’ alleged negligence and deceptive practices.
The primary focus of these lawsuits is on the severe gastrointestinal side effects associated with GLP-1 receptor agonists, such as Ozempic and Wegovy. These side effects include gastroparesis, cyclic vomiting syndrome, and other serious health issues.
Thousands of lawsuits have been filed against the manufacturers, Novo Nordisk and Eli Lilly, alleging that they failed to adequately warn consumers and healthcare providers about these risks, prioritizing profits over safety.
Recent studies have highlighted additional risks. A study published in March 2024 revealed an increased risk of aspiration pneumonia in users of GLP-1RA medications during certain medical procedures. This has led some medical centers to advise discontinuing these medications before elective procedures involving sedation.
The legal landscape is becoming increasingly complex, with mass tort lawsuits underway in federal courts, scrutinizing both the drug manufacturers and the FDA’s approval process. These cases could lead to stricter regulations and impact the future availability and perception of these drugs.
If you or a loved one have experienced adverse effects from GLP-1 receptor agonists, now is the time to seek legal advice. Contact our experienced legal team today to discuss your options and protect your rights. Our attorneys specialize in pharmaceutical litigation and have a proven track record of successfully advocating for clients harmed by unsafe medications. We will provide a thorough assessment of your case, help you navigate the complexities of mass tort litigation, and work tirelessly to ensure you receive the compensation you deserve. Don’t wait—reach out to us now for a free consultation and take the first step towards justice.
Our focus is on making sure that that you receive the attention you need and a clear path forward, all without any upfront costs. Our no-cost, no-obligation consultation outlines the steps we will take to fight for the justice and compensation you deserve.
DV Injury provides more than strong legal representation. We give you the support and reassurance you need during a challenging time in your life. Our goal is to ensure you’re not fighting the big corporations by yourself. We fight for you, and we don’t stop until justice is served.
You deserve the maximum amount for your distress and we do our level best to make sure you are properly compensated for pain and suffering, lost wages, medical expenses, and more. We’ve helped our clients recover hundreds of millions.
Contact us today for a free initial consultation.
We do not get paid unless you win.
Call or fill out the form below. We’ll contact you to schedule your free consulation.
